Renal afferent arterioles (Aff) from angiotensin II (AngII)-infused rabbits have enhanced contractions to AngII that are normalized by tempol (superoxide dismutase mimetic), whereas contractions to norepinephrine (NE) are normal and unaffected by tempol. Tested was the hypothesis that ␤-receptor stimulation with NE prevents enhanced reactivity and superoxide generation. Preconstricted Aff from AngII-or vehicle-infused rabbits were perfused at physiologic pressure. Aff from vehicle-infused rabbits had strong, endothelium-independent relaxations to dobutamine (␤ 1 -receptor agonist; 78 ؎ 6%; P < 0.0001; mean ؎ SD) but only weak relaxations to salbutamol (␤ 2 -receptor agonist; 13 ؎ 3%; P < 0.05) or BRL-37,344 (␤ 3 -receptor agonist; 14 ؎ 3%; P < 0.05). Contractions to NE were similar in Aff from vehicle-and AngII-infused rabbits (؊36 ؎ 5 versus ؊34 ؎ 3%; NS) and were unaffected by tempol (؊32 ؎ 4%; NS). In contrast, phenylephrine contractions (␣ 1 agonist) were enhanced in Aff from AngII-infused rabbits (؊59 ؎ 6 versus ؊46 ؎ 4%; P < 0.05) and normalized by tempol. NE contractions in Aff from AngII-infused rabbits (؊34 ؎ 4%) were enhanced (P < 0.01) by propranolol (nonselective ␤ antagonist; ؊53 ؎ 6%), CGP-20,712A (selective ␤ 1 -receptor antagonist; ؊61 ؎ 9%), or Rp-cAMP (competitive inhibitor of cAMP; ؊56 ؎ 4%); were normalized by tempol; but were unaffected by ICI-118,551 (selective ␤ 2 -receptor antagonist) or SR-59,230A (selective ␤ 3 -receptor antagonist). Superoxide generation in Aff from AngII-infused rabbits that were assessed from ethidium:dihydroethidium was enhanced by addition of CGP-20,712A to NE but was normalized by tempol. Aff have robust ␣ 1 -receptor contraction and ␤ 1 -receptor dilation. NE elicits ␤ 1 signaling via cAMP that moderates oxidative stress and contractions in Aff from AngII-infused rabbits.
O xidative stress suggests an increased production or a decreased metabolism of reactive oxygen species (ROS). Superoxide (O 2 ⅐ Ϫ ) mediates enhanced contractility in many models of hypertension (1, 2) . O 2 ⅐ Ϫ is metabolized by superoxide dismutase (SOD) to H 2 O 2 . Harrison and colleagues (1, 3) showed that, whereas prolonged infusion of angiotensin II (AngII) generates O 2 ⅐ Ϫ in blood vessels, infusions of norepinephrine (NE) fail to induce vascular oxidative stress. Moreover, administration of permanent SOD reverses hypertension in the AngII-induced but not the NE-induced rat model (3) . They concluded that AngII selectively induces vascular oxidative stress, which contributes to hypertension. Relatively low rates of infusion of AngII into mice (4), rats (1, 5, 6) , rabbits (7), or humans (8) increase BP gradually ("slow pressor response"). This is considered a model of human hypertension because the plasma levels of AngII increase only within a physiologic range of 50 to 100% (9) . The hypertension entails a renal mechanism because it depends on salt intake (10) and an enhanced vascular reactivity of the renal afferent arteriole (Aff) to AngII (11) . Unlike AngII, infusion of NE leads to tachyphylaxis and a decreased BP response (8) . The AngII slow pressor response has been related to ROS because it is prevented by co-infusion of the permeant SOD mimetic nitroxide tempol (4, 6) .
Low rates of infusion of the thromboxane-prostanoid receptor (TP-R) mimetic U-46,619 (12) or endothelin-1 (ET-1) (13) also elicit slow pressor responses that are accompanied by oxidative stress. Moreover isolated, pressurized Aff that are dissected from the kidneys of rabbits that are undergoing an AngII slow pressor response have an enhanced contractility not only to AngII but also to ET-1 and U-46,619 (11) that depend on O 2 ⅐ Ϫ because they are moderated or prevented by bath addition of the permanent SOD mimetic nitroxide tempol (11) . In contrast, contractions to bath addition of NE or high [K ϩ ] are not enhanced in Aff from AngII-infused rabbits and are not affected by tempol. This suggests an alternative explanation for the previous studies: Prolonged AngII infusion generates vascular ROS that enhance the responses to AngII and also to a number of other G protein-coupled receptor agonists such as ET-1, U-46,619, and phenylephrine (PE). In contrast, activation of ␤-adrenergic receptors by NE prevents the generation of ROS and consequently the enhanced contraction. This suggests that the unique response is to NE rather than to AngII. Therefore, these studies were undertaken to investigate the hypothesis that activation of a specific subtype of ␤-adrenergic receptors by NE prevents ROS-induced enhanced contractility of Aff from AngII-infused rabbits.
Materials and Methods

Animal Protocols
The protocol was approved by the Georgetown University Animal Care and Use Committee. Male New Zealand white rabbits (1.8 to 2.1 kg) were maintained on tap water and standard diet (Na ϩ content 0.4 g/100g) and prepared as described previously (11) . Under local anesthesia with EMLA cream (2.5% lidocaine and 2.5% prilocaine), sterile osmotic minipumps (Alzet, DURET Corp., Cupertino, CA) were implanted subcutaneously in rabbits (n ϭ 6 per group) to infuse vehicle (0.154 M NaCl) or human AngII (Peninsula Laboratories, San Carlos, CA) at 200 ng/kg per min (AngII) for 12 to 14 d.
Isolation and Microperfusion of Aff
Rabbits were anesthetized with xylazine (10 mg/kg intramuscularly), ketamine (50 mg/kg intramuscularly), and pentobarbital sodium (10 mg/kg intravenously) followed by heparin (1000 USP intravenously) for anticoagulation. Microdissection and microperfusion at 60 mmHg of Aff were performed as described previously (14, 15) . Each experiment in each series used a separate arteriole.
Experimental Protocol
The first aim was to test the role of the ␤-adrenoreceptor subtype and the endothelium in the relaxation of Aff from vehicle-infused rabbits (n ϭ 6 per group). Aff were preconstricted by 60 to 70% from control luminal diameter with PE (10 Ϫ6 M; ␣ 1 -receptor agonist). Thereafter, dobutamine (10 Ϫ7 M; ␤ 1 -receptor agonist) (16), salbutamol (10 Ϫ6 M; ␤ 2 -receptor agonist) (17) , or BRL-37,344 (BRL; 10 Ϫ6 M; ␤ 3 -receptor agonist) (17) was added to the bath. These dosages were selected in pilot studies to show Ͻ90% of maximal responses. Vessels were observed for 3 to 5 min, which allowed for maximal responses. Parallel studies were undertaken in vessels (n ϭ 6) that were denuded of endothelium by microperfusion with 0.1% goat anti-human von Willebrand factor antibody plus 2% guinea pig serum complement for 10 min (14, 18) . This entirely prevents relaxation responses to acetylcholine but leaves intact responses to sodium nitroprusside (14 (17) was added to the bath.
The seventh aim was to test the hypothesis that ␤ 1 -adrenergic receptor activation during NE prevents an increase in O 2 ⅐ Ϫ generation in Aff.
O 2 ⅐ Ϫ generation was assessed by fluorescence microscopy of perfused Aff (n ϭ 6) with dihydroethidium (DHE). DHE is freely permeable to cells. It is oxidized by O 2 ⅐ Ϫ to the highly fluorescence compound ethidium, which is trapped intracellularly and intercalated into DNA (24) . The conversion of DHE to ethidium was quantified by a dualwavelength determination using an excitation wavelength of 380 nm and an emission wavelength of 460 nm for DHE and an excitation wavelength of 535 nm and an emission wavelength of 605 nm for ethidium (25) . Single-agent signal capture was achieved by cycling at 3-s intervals between a 460-and 605-nm filter. Changes in O 2 ⅐ Ϫ were expressed as the ratio of ethidium:DHE fluorescence (26) . The system used an Olympus IX70 fluorescence microscope equipped with dual photomultipliers (PMT, Photon Technology Int., Lawrenceville, NJ). Excitation was provided by a 75-W xenon arc lamp using a 380/460 nm wavelength combination isolated with a computer-controlled monochromator. Ethidium and DHE emit blue and red light, respectively, that was directed to a dual PMT assembly by a beam splitter that directed light to the two separate PMT using a 400-nm dichroic mirror and using barrier filters centered at 460 and 605 nm, respectively. The ratio of ethidium:DHE was monitored in real time and recorded by software (Felix32; Photon Technology Int.). For testing of ␤ 1 -adrenergic receptor activation of ROS generation during NE action, Aff from AngII-infused rabbits were cannulated and load with HBSS that contained DHE (10 Ϫ5 M) and glutamine (10 mM).
After 30 min for equilibration, the ratio of ethidium:DHE was assessed for 10-min periods during vehicle and after 30 min of incubation with NE (10 Ϫ7 M), 30 min of incubation with NEϩCGP (10 Ϫ8 M, ␤ 1 -adrenergic receptor blocker), and 30 min of incubation with NE plus a combination of CGP and tempol (10 Ϫ4 M). A separate set of Aff were incubated throughout with a vehicle as a time control.
Drugs and Solutions
All solutions were prepared fresh daily. Reagents were purchased from Sigma (St. Louis, MO). Rp-cAMP was obtained from Biolog-Life Science Institute (La Jolla, CA). Earle's Deficient BME Solution was used for dissection. It contains 8.89 g/L NaCl, 26 mM NaHCO 3 , 2 mM l-glutamine, and 5% BSA (pH 7.40 to 7.45). It was filtered (0.8 m) and prepared fresh daily. MEM solution that contained 26 mM NaHCO 3 and 5% BSA was used for perfusion, and MEM that contained 26 mM NaHCO 3 and 0.15% BSA was used for superfusion. HBSS was purchased from Invitrogen (Carlsbad, CA).
Statistical Analyses
Statistical tests of the percentage of vasoconstriction or vasodilation used 2 ϫ 2 factorial repeated-measures ANOVA (Statistical Software v.5.0; University of Hamburg, Hamburg, Germany). When appropriate, post hoc comparisons between groups were made with t test. Statistical significance was defined as P Ͻ 0.05. Data are presented as mean Ϯ SD.
Results
The diameter of Aff from AngII-and vehicle-infused rabbits was similar in the basal state (17.3 Ϯ 1.2 versus 16.9 Ϯ 1.2 m; NS) and during NAK (6.5 Ϯ 0.5 versus 6.3 Ϯ 0.6 m; NS)
␤-Adrenoreceptors Subtype Mediating Relaxation of Aff
Dobutamine (10 Ϫ7 M; a selective ␤ 1 -adrenergic receptor agonist) potently relaxed PE-constructed Aff (78 Ϯ 6%; P Ͻ 0.001), whereas salbutamol (10 Ϫ6 M; selective ␤ 2 -adrenergic receptor agonist) had a significantly (P Ͻ 0.001) weaker effect (13 Ϯ 3%; P Ͻ 0.05) as did BRL (10 Ϫ6 M; selective ␤ 3 -adrenergic receptor agonist, 14 Ϯ 3; P Ͻ 0.05). None of these relaxations was affected by endothelium removal ( Figure 1A ). Dobutamine induced a dosage-dependent, endothelium-independent relaxation, with an IC 50 of 4.99 ϫ 10 Ϫ7 Ϯ 2.03 ϫ 10 Ϫ9 M ( Figure 1B) .
We conclude that ␤-receptor vasodilation in rabbit Aff is mediated predominantly by ␤ 1 -adrenergic receptors via an endothelium-independent mechanism.
Role of O 2 ⅐ Ϫ in Contractions of Aff to NE and PE
Compared with Aff from vehicle-infused rabbits, Aff from AngII-infused rabbits had similar contractions to NE (Ϫ36 Ϯ 5 versus Ϫ34 Ϯ 3%; NS) but enhanced contractions to PE (Ϫ59 Ϯ 6 versus Ϫ46 Ϯ 4%; P Ͻ 0.05; Figure 2 ). Bath addition of tempol did not modify the diameter in the basal state or during NAK. Bath addition of tempol to Aff from AngII-infused rabbits did not affect their response to NE but reduced their contractions to PE to the level of Aff from vehicle-infused rabbits (49 Ϯ 5 versus 46 Ϯ 4; NS). We conclude that PE generates O 2 ⅐ Ϫ in Aff from AngII-infused rabbits, which enhances their responsiveness, whereas NE does not.
Effect of ␤-Adrenergic Receptor Blockade on Contractions of Aff to NE
Aff from rabbits that were infused with vehicle or AngII had similar contractions to KCl and NE (Figure 3 ). Bath addition of tempol, propranolol, or tempol plus propranolol did not modify contractions of Aff to KCl in either group and did not modify contractions to NE in vehicle-infused rabbits. However, propranolol enhanced contractions to NE in Aff from AngIIinfused rabbits (Ϫ34 Ϯ 3 versus Ϫ53 Ϯ 6%; P Ͻ 0.01; Figure 3B ). This effect of propranolol was prevented by tempol (53 Ϯ 6%; NS versus propranolol alone). We conclude that activation of ␤-adrenergic receptors in Aff from AngII-infused rabbits prevents enhanced O 2 ⅐ Ϫ -dependent contractions to NE.
Role of cAMP in Moderating NE Contraction of Aff from AngII-Infused Rabbits
KCl contractions of Aff from AngII-infused rabbits were unaffected by tempol, Rp-cAMP, or tempol plus Rp-cAMP (Figure 4) . Whereas tempol did not affect NE contractions of Aff from AngII-infused rabbits, these contractions were enhanced by Rp-cAMP (Ϫ38 Ϯ 3 versus Ϫ56 Ϯ 4%; P Ͻ 0.01). This effect of Rp-cAMP was blocked by bath addition of tempol (Ϫ37 Ϯ 6%; NS versus tempol alone). We conclude that cAMP that is generated in Aff from AngII-infused rabbits mediates the effects of ␤-adrenergic receptors to inhibit O 2 ⅐ Ϫ generation and enhance NE contractions.
Subtype of ␤-Adrenergic Receptor Preventing Enhanced Contractions to NE in Aff from AngII-Infused Rabbits
NE contractions of Aff from AngII-infused rabbits were unaffected by tempol alone, ICI (selective ␤ 2 -adrenergic receptor selective ␤ 1 -adrenergic receptor antagonist) enhanced NE contractions (Ϫ40 Ϯ 3 versus Ϫ61 Ϯ 9%; P Ͻ 0.001). This effect was prevented by tempol (Ϫ39 Ϯ 5%; NS versus tempol alone). We conclude that the ␤-adrenergic receptors that inhibit O 2 ⅐ Ϫ generation and enhance contractions to NE in Aff from AngIIinfused rabbits are subtype I.
Specificity of CGP as a ␤ 1 -Adrenergic Receptor Antagonist
The addition of CGP (10 Ϫ8 M) to the bath of Aff from vehicleinfused rabbits prevented the relaxation to dobutamine (10 Ϫ7 M; selective ␤ 1 -adrenergic receptor agonist; 78 Ϯ 5 versus 3 Ϯ 5%; P Ͻ 0.001) but not to salbutamol (selective ␤ 2 -adrenergic receptor agonist) or BRL (selective ␤ 3 -receptor agonist) ( Figure  6 ). We conclude that CGP is a selective ␤ 1 -adrenergic receptor antagonist in this preparation. 
Discussion
We confirm that prolonged infusion of AngII does not modify NE contractions of Aff, in contrast to the enhanced responses reported with AngII, ET-1, and U-46,619 (7, 11) . The new findings are that the absence of an enhanced response to NE in these vessels cannot be ascribed to a protective role of ␣ 1 -adrenergic receptor stimulation because the contractile response to phenylephrine is enhanced similarly to AngII, ET-1, and U-46,619. Blockade of ␤-adrenergic receptors unmasks an enhanced NE response in Aff from AngII-infused rabbits, similar to PE. This implicates ␤-adrenergic receptors in moderating the responsiveness. Because this effect is reversed by incubation with tempol, it can be ascribed to ␤-adrenergic receptordependent inhibition of vascular O 2 ⅐ Ϫ generation. The ␤-adrenergic receptor subtype that is responsible is identified as type I because the ␤ 1 -adrenergic receptor agonist dobutamine causes a much more powerful relaxation of preconstricted Aff than ␤ 2 -or ␤ 3 -adrenergic agonists and the ␤ 1 -adrenergic receptor antagonist CGP enhances NE contractions in Aff from AngII-infused rabbits, whereas ␤ 2 -or ␤ 3 -adrenergic receptor antagonists are ineffective. Fluorescence microscopy demonstrated that blockade of ␤ 1 -adrenergic receptors during stimulation with NE enhanced O 2 ⅐ Ϫ in the perfused Aff, which was restored by incubation with tempol. The effects of ␤ 1 -adrenergic receptors to moderate contractions are independent of the endothelium. Because this effect is blocked by Rp-cAMP, it seems to be mediated by generation of cAMP. Therefore, the absence of an enhanced response to NE in Aff from AngII-infused rabbits is related to ␤ 1 -adrenergic receptors that activate cAMP and counteract
Tempol is freely membrane permeable and acts as a catalytic SOD mimetic (15) . Tempol fully prevents the graded vasoconstriction of isolated, perfused Aff to the O 2 ⅐ Ϫ -generating quinolone paraquat (19) . Studies with fluorescence indicators of O 2 ⅐ Ϫ have confirmed that tempol, in the dosage used in this study, fully prevents the generation of O 2 ⅐ Ϫ in isolated, perfused vasa recta that are stimulated with AngII (27) . This was confirmed in this study, in which enhanced vascular O 2 ⅐ Ϫ generation by NE during ␤ 1 -adrenergic receptor blockade was normalized by bath addition of 10 Ϫ4 M tempol.
Contractions to NE in Aff are mediated via ␣-adrenergic receptor-dependent transmembrane increases in intracellular [Ca 2ϩ ] (28) and release of Ca 2ϩ from intracellular stores (29) . The finding that PE seemed to have enhanced ROS generation in Aff from AngII-infused rabbits is consistent with its effect to increase ROS generation in vitro in vascular smooth muscle cells (30) and in vivo in rat aorta, where the effect is accompanied by upregulation of p47 phox expression and mediated via NADPH oxidase (31) .
Within the cardiovascular system, ␤ 1 -adrenergic receptors are expressed predominantly in cardiomyocytes, where they mediate chronotropic and inotropic effects (32), whereas ␤ 2 -adrenergic receptors are expressed predominantly in peripheral blood vessels, where they mediate vasorelaxation (32) . ␤ 3 -Adrenergic receptors can cause endothelium-dependent relaxation of coronary microvessels but have a less defined role presently in the cardiovascular system (33) . Therefore, the finding that vasorelaxation of Aff was much more prominent with a ␤ 1 -than with a ␤ 2 -or ␤ 3 -adrenergic receptor agonist would not be expected from Land's hypothesis. This may relate to a selective action of ␤ 1 -adrenergic receptors on the terminal renal Aff, where specialized granular smooth muscle cells are stimulated to release renin predominantly by ␤ 1 -adrenergic recep- tors (34, 35) . It seems that a similar receptor activation also induces vasorelaxation of this blood vessel. Moreover, recent studies have shown predominant ␤-adrenergic receptor regulation of vascular tone by the ␤ 1 subclass in some small vessels, depending on species and site (36) . Recent studies in the rat have concluded that ␤ 1 , not ␤ 2 -adrenergic receptors predominate on vascular smooth muscle cells of mesenteric resistance vessels (17) and renal microvessels and macula densa epithelium (37) . Functionally, the ␤ 1 -adrenergic receptor is the predominant class mediating vasodilation in the small blood vessels of the kidney and mesentery of rats or mice (17, 38) . In an in vivo analysis in humans, Wellstein et al. (39) estimated that 77% of ␤-adrenergic receptor-related hypotension is mediated via ␤ 1 -adrenergic receptors and 23% via ␤ 2 -adrenergic receptors. Studies in the rabbit have confirmed that ␤ 1 -adrenergic receptor blockade with atenolol inhibits the renin release in response to angiotensin receptor blockade, which is considered to be an effect that is mediated at the terminal Aff (40) . The effect of ␤ 1 -adrenergic receptors to inhibit ROS generation seems to depend on protein kinase A (PKA) because it is blocked by Rp-cAMP. Studies in the isolated mesenteric resistance vessel of the rat have shown that ␤ 1 -adrenogenic receptors induce vasorelaxation via separate PKA-dependent and -independent pathways (22) .
Within the peripheral circulation, ␤-adrenergic receptor stimulation can lead to endothelium-dependent or -independent vasorelaxation. Removal of the endothelium from the terminal renal Aff did not modify the vasorelaxation to ␤ 1 -, ␤ 2 -, or ␤ 3 -adrenergic receptor stimulation, indicating that relaxation at this site is endothelium independent. This conclusion held for the entire dosage-response range for the ␤ 1 -adrenergic receptor agonist dobutamine. This is consistent with recent conclusions from studies with fluorescence covalent ligands for ␤ 1 -adrenergic receptors that locate these receptors on vascular smooth muscle cells of rat mesenteric resistance vessels in the plasma membrane, Golgi, endoplasmic reticulum, and perinuclear spaces (17) .
Whereas epinephrine is a potent agonist of ␤ 1 -and ␤ 2 -adrenergic receptors, NE activates predominantly ␤ 1 -adrenergic receptors. This is consistent with the finding that the ␤ 1 -adrenergic receptor antagonist CGP increased NE vasoconstriction markedly in Aff from AngII-infused rabbits, whereas a ␤ 2 -or ␤ 3 -adrenergic receptor antagonist was not effective. CGP was validated as a selective ␤ 1 -adrenergic receptor antagonist because it prevented the response to the ␤ 1 -adrenergic receptor agonist dobutamine without affecting the response to a ␤ 2 -or ␤ 3 -adrenergic receptor agonist.
Whereas there is much evidence of receptor-dependent stimulation of vascular ROS by agonists such as PE, AngII, ET-1, or U-46, 619, less is known concerning receptor-mediated antioxidant defense, for example by catecholamines. Activation of dopamine D 1 and D 5 receptors in rat renal vascular smooth muscle cells inhibits ROS generation (41) . D 5 receptor activation in human embryonic kidney HEK-293 cells inhibits ROS generation by activation of heme oxygenase-1 (42) and inhibition of the assembly and activity of NADPH oxidase (43) . Because the D 5 receptor-mediated inhibition of ROS generation is independent of cAMP in HEK-293 cells, whereas D 1 -like receptormediated inhibition of ROS in renal vascular smooth muscle cells is mediated in part by cAMP, the D 1 dopamine receptor, like the ␤ 1 -adrenergic receptor, may exert their antioxidant effects via cAMP.
If our finding that ␤ 1 receptors protect the renal Aff of AngII-infused rabbits from NE-induced oxidative stress and associated enhanced contractility is relevant to other microvessels, then this may help to explain why prolonged treatment of hypertension with a ␤ 1 -adrenergic receptor antagonist, atenolol, in contrast to the antioxidant calcium channel blocker, amlodipine (44) , fails to restore endothelial function or reverse remodeling of subcutaneous microvessels (45) . Moreover, atenolol fails to provide effective cardiovascular protection in trials of hypertensive patients (46) . This has led some authorities to recommend that ␤ 1 -adrenergic receptor antagonists no longer be prescribed as primary therapy for hypertension (47) . A potential explanation that requires study is that such therapy prevents the counterbalance of ␣-adrenergic receptor-mediated ROS generation during NE stimulation by activated ␤ 1 -adrenergic receptors.
